Bausch Lomb Corporation(BLCO-T)
TSX

Today's Change
Real-Time Last Update
Day Low21.62
Day High21.95
Open:21.76
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Stock Target Advisor
Canadian Analyst Updates: June 2nd, 2026
Canadian Analyst Updates: June 2nd, 2026
SYNDTGAM
Tuesday’s analyst upgrades and downgrades
Business Wire
Bausch + Lomb Launches Blink® Triple Care Preservative Free Lubricant Eye Drops in the United States
Baystreet
Stocks in play: Bausch + Lomb Corporation
Business Wire
Bausch + Lomb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Business Wire
Bausch + Lomb Announces 2026 Annual Meeting of Shareholder Results
Baystreet
Stocks in play: Bausch + Lomb Corporation
Business Wire
Bausch + Lomb Launches PreserVision AREDS3™ Eye Vitamins in the United States
Business Wire
Bausch + Lomb Announces Second R&D “Teach-in” Webinar
Baystreet
Stocks in play: Bausch + Lomb Corporation
Business Wire
Bausch + Lomb to Feature More Than 40 Scientific Studies at the 2026 Association for Research in Vision and Ophthalmology Annual Meeting
Business Wire
Bausch + Lomb Announces First-Quarter 2026 Results, Raises Guidance Based on Strong Performance and Positive Outlook
Business Wire
Bausch + Lomb Announces Published Review Examining the Role of B Vitamins in Reducing Risk and Progression of Age-Related Macular Degeneration
Business Wire
Bausch + Lomb Releases 2025 Sustainability Impact Report
Baystreet
Stocks in play: Bausch + Lomb Corporation
Business Wire
Bausch + Lomb Reports Nearly 725,000 Pounds of Contact Lens, Lens Care and Eye Care Materials Collected and Recycled Through ONE By ONE Recycling Program
Baystreet
Stocks in play: Bausch + Lomb Corporation
Business Wire
Bausch + Lomb Receives FDA 510(k) Clearance for Bi-Blade+™ Dual-Port Vitrectomy Cutter and Adaptive Fluidics™ Advanced Update
Baystreet
Stocks in play: Bausch + Lomb Corporation

Profile

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.